Na(+)/H(+) exchanger activity and dopamine D(1)-like receptor function in two opossum kidney cell clonal sublines.
OBJECTIVE
The enhanced renal reabsorption of Na(+) in hypertension is accompanied by a defective transduction of the renal dopamine D(1) receptor signal. The present study evaluated the response of the Na(+)/H(+) exchanger to dopamine D(1)-like receptor stimulation in two clonal subpopulations of opossum kidney (OK) cells (OK(LC) and OK(HC)) that are functionally different with respect to their ability to transport Na(+).


METHODS
Na(+)/H(+) exchanger activity was assayed as the initial rate of intracellular pH (pH(i)) recovery after an acid load. The presence of D(1)-like receptors was measured in saturation experiments with [(3)H]-Sch 23390 in cell membranes.


RESULTS
V(max) values (in pH units/s) for Na(+)-dependent pH(i) recovery in OK(HC) cells (0.00521+/-0.0004) were twice those in OK(LC) (0.00202+/-0.0001), with similar K(m) values. The selective D(1)-like receptor agonist SKF 38393 (30 to 3000 nM) attenuated the Na(+)/H(+) exchanger activity in OK(HC) cells more potently than in OK(LC) cells.GTPgammaS and forskolin were equipotent in inhibiting the Na(+)/H(+) exchanger in OK(HC) cells and OK(LC) cells. The SKF 38393-induced increase in cyclic AMP levels in OK(HC) cells was greater than in OK(LC) cells. B(max) values for the binding of [(3)H]-Sch 23390 in OK(HC) cells were twice that in OK(LC) cells, with similar K(D) values. The abundance of G(Salpha) protein in cell membranes of OK(HC) cells was similar to that in OK(LC) cells.


CONCLUSIONS
The enhanced sensitivity of the Na(+)/H(+) exchanger to inhibition by the D(1)-like receptor agonist in OK(HC) cells correlated positively with the high density of D(1)-like binding sites and the enhanced production of cyclic AMP during D(1)-like receptor stimulation in OK(HC) cells.
Gomes
Pedro
P
Institute of Pharmacology Therapeutics, Faculty of Medicine, Porto, Portugal.
Soares-da-Silva
Patrício
P
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000031:analogs & derivatives / Q000494:pharmacology; D000584:Amiloride / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001552:Benzazepines / Q000737:chemistry / Q000378:metabolism; D001665:Binding Sites; D001692:Biological Transport / Q000187:drug effects / Q000502:physiology; D002999:Clone Cells; D000242:Cyclic AMP / Q000378:metabolism; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D019205:GTP-Binding Protein alpha Subunits, Gs / Q000032:analysis / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D015151:Immunoblotting; D007668:Kidney / Q000166:cytology / Q000378:metabolism*; D009893:Opossums / Q000378:metabolism*; D017447:Receptors, Dopamine D1 / Q000378:metabolism*; D017923:Sodium-Hydrogen Exchangers / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014316:Tritium
D001552:Benzazepines; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D004791:Enzyme Inhibitors; D017447:Receptors, Dopamine D1; D017923:Sodium-Hydrogen Exchangers; D014316:Tritium; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D000584:Amiloride; D000242:Cyclic AMP; D019205:GTP-Binding Protein alpha Subunits, Gs